Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector
Sanofi's Sarclisa becomes 1st cancer drug approved for delivery via on-body injector
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
The US FDA has approved Sanofi's Sarclisa, a treatment for multiple myeloma, in a subcutaneous form administered via an on-body injector.
Coverage from Reuters, Fierce Pharma, and others emphasizes this marks the first cancer drug delivered through this type of device. The approval was reported by multiple sources, including Pharmaceutical Executive and PharmTech.com.
The impact of this approval on treatment delivery and patient experience remains to be seen; what to watch next is how this new delivery method affects Sarclisa's usage and adoption in the medical community.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. Updated just now.
Quick answers
What is Sarclisa?
Sarclisa is a treatment for multiple myeloma
What is unique about the approved form of Sarclisa?
It is delivered via an on-body injector
Which disease is Sarclisa used to treat?
Multiple myeloma
Coverage (5)
- FDA Approves Subcutaneous Sarclisa Escena Pharmaceutical Executive · 16h ago
- The Implications of Isatuximab-irfc’s FDA Approval for Multiple Myeloma PharmTech.com · 16h ago
- Subcutaneous Sarclisa Escena Receives FDA Nod for Multiple Myeloma Medical Professionals Reference · 16h ago
- US FDA approves Sanofi's wearable injector form of blood cancer drug Reuters · 16h ago
- Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector Fierce Pharma · 16h ago broke it first
People, places & organizations
Topics
Related trends
Sanofi under antitrust probe as European Commission kicks off formal proceedings
Sanofi faces EU antitrust probe over flu vaccine marketing